m6A Target Gene Information

General Information of the m6A Target Gene (ID: M6ATAR00781)
Target Name Vasopressin V2 receptor (Avpr2/V2R)
Synonyms
ADHR; DIR; DIR3; V2R; Vasopressin V2 receptor; V2R ; AVPR V2 ; Antidiuretic hormone receptor ; Renal-type arginine vasopressin receptor
    Click to Show/Hide
Gene Name Avpr2
Chromosomal Location Xq28
Family G-protein coupled receptor 1 family, Vasopressin/oxytocin receptor subfamily
Function
Receptor for arginine vasopressin. The activity of this receptor is mediated by G proteins which activate adenylate cyclase. Involved in renal water reabsorption.
    Click to Show/Hide
Gene ID 554
Uniprot ID
V2R_HUMAN
HGNC ID
HGNC:897
Ensembl Gene ID
ENSG00000126895.16
KEGG ID
hsa:554
Full List of m6A Methylation Regulator of This Target Gene and Corresponding Disease/Drug Response(s)
Avpr2 can be regulated by the following regulator(s), and cause disease/drug response(s). You can browse detail information of regulator(s) or disease/drug response(s).
Browse Regulator
Browse Disease
Methyltransferase-like 3 (METTL3) [WRITER]
 Regulator Info 
Representative RIP-seq result supporting the interaction between Avpr2 and the regulator
Cell Line MDA-MB-231 Homo sapiens
Regulation logFC: 4.52E+00 GSE60213
In total 1 item(s) under this regulator
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene [1]
Response Summary Mettl3 activates the cyst-promoting c-Myc and cAMP pathways through enhanced c-Myc and Vasopressin V2 receptor (Avpr2/V2R) mRNA m6A modification and translation. Thus, Mettl3 promotes Autosomal dominant polycystic kidney disease and links methionine utilization to epitranscriptomic activation of proliferation and cyst growth.
Target Regulation Up regulation
Responsed Disease Polycystic kidney disease ICD-11: GB81
 Disease Info 
In-vitro Model mIMCD-3 Normal Mus musculus CVCL_0429
In-vivo Model The clone, with one wild-type Mettl3 allele and one L1L2_Bact_P cassette inserted allele, was injected into C57BL/6 blastocysts. Mettl3-targeted mouse line was established from a germline-transmitting chimera. The chimeric mouse was crossed to C57BL/6 Flp mice to excise the neomycin resistance system.
Polycystic kidney disease [ICD-11: GB81]
 Disease Info 
In total 1 item(s) under this disease
Experiment 1 Reporting the m6A-centered Disease Response [1]
Response Summary Mettl3 activates the cyst-promoting c-Myc and cAMP pathways through enhanced c-Myc and Vasopressin V2 receptor (Avpr2/V2R) mRNA m6A modification and translation. Thus, Mettl3 promotes Autosomal dominant polycystic kidney disease and links methionine utilization to epitranscriptomic activation of proliferation and cyst growth.
Responsed Disease Polycystic kidney disease [ICD-11: GB81]
Target Regulator Methyltransferase-like 3 (METTL3) WRITER
 Regulator Info 
Target Regulation Up regulation
In-vitro Model mIMCD-3 Normal Mus musculus CVCL_0429
In-vivo Model The clone, with one wild-type Mettl3 allele and one L1L2_Bact_P cassette inserted allele, was injected into C57BL/6 blastocysts. Mettl3-targeted mouse line was established from a germline-transmitting chimera. The chimeric mouse was crossed to C57BL/6 Flp mice to excise the neomycin resistance system.
References
Ref 1 A methionine-Mettl3-N(6)-methyladenosine axis promotes polycystic kidney disease. Cell Metab. 2021 Jun 1;33(6):1234-1247.e7. doi: 10.1016/j.cmet.2021.03.024. Epub 2021 Apr 13.